The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Liso-cel vs tisa-cel in third-line DLBCL treatment
John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, outlines the results of a retrospective study comparing lisocabtagene maraleucel (liso-cel) and tisagenlecleucel (tisa-cel) in patients with diffuse large B-cell lymphoma (DLBCL) in the third-line setting. Whilst both CAR-T therapies had a favorable safety profile, liso-cel appeared to be more effective. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Karyopharma, DSB; Honoraria from Karyopharma, Merck; Research funding from Merck
